Formycon AG

FYB

DE000A1EWVY8

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 12:51:13 21/01/2026 GMT			5-day change	1st Jan Change
22.72 ^EUR	-1.41%		-11.07%	-12.11%

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE

FORMYCON : RBC maintains a Buy rating

Published on 11/13/2025 at 09:08 am GMT

MarketScreener with dpa-AFX Analyser

FORMYCON AG

-1.41%

Natalia Webster from RBC retains his positive opinion on the stock with a Buy rating. The target price is still set at EUR 51.

Latest news about Formycon AG

12-23	Formycon Obtains US FDA Approval for Interchangeable Lucentis Biosimilar	MT
12-23	Formycon AG - FDA approves biologics license application (BLA) for additional ranibizumab biosimilar under trade name Nufymco	RE
12-23	Formycon AG and Bioeq AG Announce the U.S. Food and Drug Administration Approves Nufymco®?	CI
12-22	INDEX MONITOR: Numerous Changes in MDax and SDax - Dax Remains Unchanged	DP
12-18	Formycon AG(XTRA:FYB) dropped from Germany SDAX (Total Return) Index	CI
12-09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
12-09	Formycon AG and Zydus Lifesciences Limited Partner for Exclusive Licensing and Supply Agreement of FYB206, a Biosimilar to Keytruda® (Pembrolizumab), in the U.S. and Canada	CI
12-09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
12-09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206	RE
12-09	Formycon Ag and Zydus Lifesciences Limited Enter into Strategic Partnership for the Exclusive Licensing and Supply of Checkpoint Inhibitor Fyb206	CI
12-04	Formycon AG and MS Pharma Sign Exclusive Commercialization Partnership for Keytruda®? Biosimilar Candidate FYB206 for the MENA Region	CI
12-04	Formycon Secures First Marketing Partnership for Keytruda Biosimilar	DP
12-04	Formycon, MS Pharma Enter Licensing Deal for Keytruda Biosimilar in MENA	MT
12-04	Stoxx Ltd. announces December 2025 review results of Dax indices	RE
12-04	Newcomers TKMS and Aumovio Join MDax; Dax Remains Unchanged	RE
12-04	Formycon and MS Pharma sign exclusive commercialization partnership for Keytruda® biosimilar candidate FYB206 for MENA region	RE
11-24	FORMYCON : Berenberg remains its Buy rating	ZD
11-24	Formycon Appoints NTC as Exclusive Commercial Partner for Eylea Biosimilar in Italy	MT
11-24	Ntc becomes commercialization partner for Formycon's Eylea® biosimilar FYB203/Baiama® in Italy	RE
11-24	Formycon AG and NTC S.r.l. Jointly Announce Eylea Biosimilar FYB203/Baiama®? in Italy	CI
11-20	Formycon Ag and Bioeq Ag Jointly Announce an Agreement with Sandoz Ag for the Commercialization of Epruvy in Germany	CI
11-17	FORMYCON : RBC reaffirms its Buy rating	ZD
11-17	Formycon Shares Rebound Sharply on Hopes for Dupixent Biosimilar	DP
11-17	Formycon Achieves Milestone with Biosimilar to Sanofi Blockbuster	RE
11-17	Formycon Raises Hopes with Dupixent Biosimilar Progress	DP

Formycon AG is a Germany based Company. The Company is engaged in providing biosimilar drugs and formulations. The Company focuses on treatments in ophthalmology, immunology and other chronic diseases, covering all steps of biosimilar development process, from early-stage analysis of the originator drug to the preclinical and clinical testing phases, as well as the preparation of dossiers for marketing approval.

Employees

250

Sector

Biotechnology & Medical Research

Calendar

04-22 - Q4 2025 Earnings Release (Projected)

More about the company